BMS has welcomed the recently announced listing of immunotherapy combination OPDIVO (nivolumab) in combination with YERVOY (ipilimumab) for the treatment of advanced renal cell carcinoma. …
Latest Video
New Stories
-
Lack of investment driving back-room deals
June 14, 2019 - - Latest News -
New technologies exposing flaws in HTA
June 14, 2019 - - Latest News -
Response on the use of 'opportunity cost'
June 14, 2019 - - Latest News -
Early, informed and high-quality engagement essential
June 14, 2019 - - Latest News -
Where was the 'frank and complete discussion' on rationing?
June 13, 2019 - - Latest News -
Gene technology an increasing focus
June 13, 2019 - - Latest News -
Evidence 'weaponised' through 'opportunity cost'
June 13, 2019 - - Latest News